Gary Krishnan is a seasoned biopharma leader with more than 26 years of experience spanning discovery, translational science, and R&D leadership. He spent the majority of his career at Eli Lilly, where he held senior executive roles including Chief Scientific Officer for Aging, Musculoskeletal, and Urology Research and Global Head of Translational Research for Immunology. Krishnan has advanced more than a dozen assets into clinical development, contributed to four blockbuster medicines, and led the discovery of one of the first therapies for hospitalized COVID-19 patients. He holds a PhD in biochemistry and biophysics from Texas A&M University and completed postdoctoral training at Baylor College of Medicine.